4.8 Article

Diuretic Strategies in Patients with Acute Decompensated Heart Failure

期刊

NEW ENGLAND JOURNAL OF MEDICINE
卷 364, 期 9, 页码 797-805

出版社

MASSACHUSETTS MEDICAL SOC
DOI: 10.1056/NEJMoa1005419

关键词

-

资金

  1. National Heart, Lung, and Blood Institute [HL084861, HL084875, HL084877, HL084889, HL084890, HL084891, HL084899, HL084904, HL084907, HL084931]
  2. Amgen
  3. Cytokinetics
  4. Corthera
  5. Otsuka
  6. Novartis
  7. Roche Diagnostics
  8. Medtronic
  9. Johnson Johnson
  10. Pfizer
  11. Boehringer Ingelheim
  12. XDx
  13. Scios
  14. Anexon
  15. Nile Therapeutics
  16. GE Healthcare
  17. Forest Pharmaceuticals
  18. Novella Clinical
  19. Medpace
  20. Roche
  21. Actelion Pharmaceuticals
  22. Trevena
  23. Martek Biosciences

向作者/读者索取更多资源

BACKGROUND Loop diuretics are an essential component of therapy for patients with acute decompensated heart failure, but there are few prospective data to guide their use. METHODS In a prospective, double-blind, randomized trial, we assigned 308 patients with acute decompensated heart failure to receive furosemide administered intravenously by means of either a bolus every 12 hours or continuous infusion and at either a low dose (equivalent to the patient's previous oral dose) or a high dose (2.5 times the previous oral dose). The protocol allowed specified dose adjustments after 48 hours. The coprimary end points were patients' global assessment of symptoms, quantified as the area under the curve (AUC) of the score on a visual-analogue scale over the course of 72 hours, and the change in the serum creatinine level from baseline to 72 hours. RESULTS In the comparison of bolus with continuous infusion, there was no significant difference in patients' global assessment of symptoms (mean AUC, 4236 +/- 1440 and 4373 +/- 1404, respectively; P = 0.47) or in the mean change in the creatinine level (0.05 +/- 0.3 mg per deciliter [4.4 +/- 26.5 mu mol per liter] and 0.07 +/- 0.3 mg per deciliter [6.2 +/- 26.5 mu mol per liter], respectively; P = 0.45). In the comparison of the high-dose strategy with the low-dose strategy, there was a nonsignificant trend toward greater improvement in patients' global assessment of symptoms in the high-dose group (mean AUC, 4430 +/- 1401 vs. 4171 +/- 1436; P = 0.06). There was no significant difference between these groups in the mean change in the creatinine level (0.08 +/- 0.3 mg per deciliter [7.1 +/- 26.5 mu mol per liter] with the high-dose strategy and 0.04 +/- 0.3 mg per deciliter [3.5 +/- 26.5 mu mol per liter] with the low-dose strategy, P = 0.21). The high-dose strategy was associated with greater diuresis and more favorable outcomes in some secondary measures but also with transient worsening of renal function. CONCLUSIONS Among patients with acute decompensated heart failure, there were no significant differences in patients' global assessment of symptoms or in the change in renal function when diuretic therapy was administered by bolus as compared with continuous infusion or at a high dose as compared with a low dose.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据